Autopsy report · NCT01414309

Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea

“Change in company priorities”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Respicardia, Inc.

Sponsor type

Industry

Conditions

Central Sleep Apnea; Heart Failure

Participants

5

Sites

4

Countries

Germany, United States

Trials that died the same way

• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (82% match in meaning)
• MINI-AMI: Minimizing Infarct Size With Impella 2.5 Following PCI for Acute Myocardial Infarction
  “Change in business priority” (80% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (74% match in meaning)
• 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
  “Business priorities” (71% match in meaning)
• Safety Study of Gintuit™ in Subjects Requiring Socket Grafting
  “Changes in corporate business environment” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.